IDO1 and metastatic melanoma: Although initial clinical IDO inhibition data was promising for use in conjunction with ICB [358,359], the first phase III trial of metastatic melanoma patients failed to demonstrate a survival advantage of anti-PD-1 and the IDO inhibitor epacadostat combination therapy over anti-PD-1 monotherapy [360].